U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    54,173.79
    -4,635.68 (-7.88%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Block & Leviton LLP Investigates Proposed Acquisition Involving Akcea Therapeutics, Inc.; Shareholders Should Contact the Firm

·2 min read

BOSTON, MA / ACCESSWIRE / August 31, 2020 / Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, has opened an investigation into the proposed acquisition involving Akcea Therapeutics, Inc. (NASDAQ:AKCA). In this proposed acquisition, Akcea's controlling shareholder, Ionis Pharmaceuticals, Inc., would acquire all of the outstanding shares of Akcea common stock that it does not already own for $18.15 per share in cash. Block & Leviton is investigating whether Ionis and/or members of the Akcea Board of Directors breached their fiduciary duties to ensure that the proposed transaction was entirely fair. Akcea shareholders should contact Block & Leviton for a free case evaluation.

Under the terms of the agreement, Ionis would commence a tender offer for all outstanding shares of Akcea common stock that it does not already own, approximately 24% of outstanding shares, at a price of $18.15 per share in cash. The closing of the tender offer will be subject to a majority of Akcea's shares not already owned by Ionis being tendered in the tender offer. After completion of the tender offer, Ionis would acquire the remaining Akcea shares through a second-step merger, expected to be completed in the fourth quarter of 2020. Ionis has said that it expects to fund the acquisition through existing cash resources.

If you are an Akcea shareholder and have questions about your legal rights or possess information relevant to this matter, you are encouraged to contact Block & Leviton attorneys at (617) 398-5600, by email at cases@blockleviton.com, or by visiting https://www.blockleviton.com/cases/akcea.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
Block & Leviton LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
www.blockleviton.com

SOURCE: Block & Leviton LLP



View source version on accesswire.com:
https://www.accesswire.com/604052/Block-Leviton-LLP-Investigates-Proposed-Acquisition-Involving-Akcea-Therapeutics-Inc-Shareholders-Should-Contact-the-Firm